glp 1 with insurance Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans GLP-1 Insurance - Why Employers

GLP-1 Market Size: USD 68.65 billion in 2026 | USD 195.01 billion by 2035 | CAGR: 12.3% | Leading Molecule: Semaglutide ( 52.1% revenue share) | Dominant Region: United States ( 62.8% revenue share) GLP-1 Weight Loss Drug Market Highlights: Key Data at a Glance ( 2026 ) GLP-1 Weight Loss Drug Market Size 2026 : USD 68.65 billion , forecast USD 195.01 billion by 2035 at 12.3% CAGR Dominant drug class: Dual GIP/GLP-1 Agonists (tirzepatide) and Injectable GLP-1 RA Monoagonists (semaglutide) with 78.4% combined revenue share Fastest-growing route: Oral GLP-1 formulations at 34.2% CAGR through 2035 driven by injection-free patient access expansion GLP-1 market leaders: Novo Nordisk and Eli Lilly with approximately 87% combined prescription weight management drug revenue share in 2026 Most prescribed weight loss molecule: Semaglutide (Wegovy and Ozempic) with 52.1% global GLP-1 market revenue share in 2026 FDA-approved anti-obesity GLP-1 drugs: Four molecules including semaglutide, tirzepatide, liraglutide, and oral semaglutide as of 2026 Global obesity patient pool: More than 1.1 billion adults with obesity globally

[DOI] [PubMed] [Google Scholar] 88.Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus

With diabetes diagnoses significantly increasing and obesity rates skyrocketing, there is a growing demand for effective treatments that manage blood sugar levels and promote weight loss

Vetter ML, Wadden TA, Teff KL, Khan ZF, Carvajal R, Ritter S, et al

Just prepare your documents, namely your medical records, and doctor's prescriptions

Moreover, there are concerns about the safety of GLP1 agents in terms of thyroid cancer that are mainly based on rodent studies [73, 74, 75]